Economic comparison of diagnostic antibody production in perfusion stirred tank and in hollow fiber bioreactor processes
✍ Scribed by Raisa Vermasvuori; Markku Hurme
- Publisher
- American Institute of Chemical Engineers
- Year
- 2011
- Tongue
- English
- Weight
- 423 KB
- Volume
- 27
- Category
- Article
- ISSN
- 8756-7938
- DOI
- 10.1002/btpr.676
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
The total operating costs of small‐scale monoclonal antibody production were calculated for two different upstream options and general downstream procedure based on protein A chromatography. The upstream options were a spin‐filter equipped stirred‐tank bioreactor (STR) and a hollow fiber bioreactor (HFB). Both the bioreactors were operated in perfusion mode. The total operating costs of the processes were 6,900 €/g for STR option and 6,400 €/g for the HFB option. In the both systems, the costs were dominated by expenses derived from the downstream section (almost 80%) that was almost identical in the both systems. In the upstream section, the investment depreciation was the largest cost item. The lower total costs of the HFB option were a result of lower investment costs and more concentrated product that led into savings also in downstream section. This study brings out the HFB as on viable alternative for stirred‐tank bioreactor, especially in small‐scale diagnostic monoclonal antibody production. © 2011 American Institute of Chemical Engineers Biotechnol. Prog., 2011